Moar QUANT FAMILY (Amazing Polly)
IMPORTANT!!!!!
Direct connection to now just PCR Fraud Drosten, but also to his college Sandra Ciesek
https://www.bitchute.com/embed/yJyxhFswCnuZ/
ARCHIVE OFFLINE
https://www.augsburger-allgemeine.de/panorama/Portraet-Sandra-Ciesek-ist-die-neue-Podcast-Partnerin-von-Christian-Drosten-id58068241.html
https://archive.is/mEsFm
Sandra Ciesek ist die neue Podcast-Partnerin von Christian Drosten
...
Aktuell leitet die in Goslar geborene Wissenschaftlerin das Institut für Medizinische Virologie am Universitätsklinikum in Frankfurt am Main und ist Professorin für Medizinische Virologie der Goethe-Universität. Bereits im Februar konnte die 42-Jährige mit ihrem Team nachweisen, dass auch symptomfreie Personen das Coronavirus in sich haben und somit übertragen können. Seitdem forscht sie vor allem zu Medikamenten gegen die Krankheit Covid-19 und an geeigneten Teststrategien. Im März erhielt sie von der Johanna-Quandt-Stiftung eine Fördersumme von 250.000 Euro für Coronaforschung – der Antrag wurde innerhalb von 24 Stunden bewilligt.
...
Sandra Ciesek is the new podcast partner of Christian Drosten
...
Currently, the Goslar-born scientist heads the Institute for Medical Virology at the University Hospital in Frankfurt am Main and is Professor of Medical Virology at Goethe University. Back in February, the 42-year-old and her team were able to prove that even symptom-free individuals carry the coronavirus and can thus transmit it. Since then, she has primarily been researching drugs against the Covid-19 disease and suitable testing strategies. In March, she received a grant of 250,000 euros from the Johanna Quandt Foundation for corona research - the application was approved within 24 hours.
...
I hope the Nazi-forced-labor-money was worth it.
Back in February, the 42-year-old and her team were able to prove that even symptom-free individuals carry the coronavirus and can thus transmit it
And that seems to be fake science, see study from China.
Wow, these people were really fast. Drosten with his fraud PCR test and this bitch with her somehow finding out that there are infectious asymptomatic people.
https://www.stiftung-charite.de/en/
And here these Nazi-fucks are even part of the Foundation Charité.
Johanna Quandt (died AUG 3rd 2015)
Prof. Dr. E. Jürgen Zöllner - Chairman of the Board of Trustees
Prof. Dr. Detlev Ganten - Honorary Chairman of the Board of Trustees
Prof. Dr. Heyo Kroemer - Executive Board Chairman, Charitè - Universitätsmedizin Berlin since September 1st 2019.
Astrid Lurati - Hospital Director, Charité - Universitätsmedizin Berlin
Prof. Dr. Brigitte Oetker - Editor
Prof. Dr. Axel R. Pries - Dean of the Medical Faculty, Charité Universitätsmedizin Berlin
Stefan Quandt- Entrepreneur, Vice Chairman of the Board of Trustees
Prof. Dr. Jens Schneider-Mergener - University Professor, Charité - Universitätsmedizin Berlin and Founder of Jerini AG
It gets even better:
Jasmin QUANDT - Scientist at BioNTech
https://de.linkedin.com/in/jasmin-quandt-539625182
https://archive.is/ivexP
Jasmin Quandt
Scientist bei BioNTech SE
Mainz, Rhineland-Palatinate, Germany
About
I am a Biochemist/Biologist by training with 11 years of experience in Tumor Immunology Research. I have a particularly strong interest in investigating topics in immune oncology that could pave the way for clinical applications and new drug development. After my PhD studies at the German Cancer Research Center in the field of Translational Tumor Immunology, I was seeking experiences abroad as a Postdoctoral Researcher in the United States. Recently I ventured into the exciting world of cooperate (cancer) vaccine development.
Through my work in this exciting, interdisciplinary research field I was able to gain expertise in immune response readout technologies, tumor models, immunological assessment of patient material, and molecular techniques. Collaborations with clinicians and other life science disciplines as well as sharing my knowledge through teaching and instructing others I happily welcome on my journey as I can only learn from them myself.
I am always curious exploring new avenues of how to contribute to impactful biomedical research and applications.
Experience
BioNTech SE
Scientist
Company Name
BioNTech SE ·Full-time
Dates Employed Apr 2020 – Present
Employment Duration ·1 yr 5 mos
Location Mainz, Rheinland-Pfalz, Deutschland
Postdoctoral Research Scholar
Company Name
University of Chicago ·Full-time
Dates Employed May 2015 – Apr 2020
Employment Duration ·5 yrs
Location Chicago, IL, USA
Investigating the epigenetic re-programming of regulatory T cells (Tregs) through Wnt-signaling activation in inflammatory bowel disease and colorectal cancer
DKFZ German Cancer Research Center
Total Duration 5 yrs 6 mos
Title Wissenschaftliche Mitarbeiterin
Full-time
Dates Employed Nov 2014 – Apr 2015
Employment Duration ·6 mos
Location Heidelberg, Baden-Württemberg, Deutschland
Title Forschende Doktorandin/PhD Student
Full-time
Dates Employed Nov 2009 – Oct 2014
Employment Duration ·5 yrs
Location Heidelberg
Development of a pre-clinical long-peptide vaccine against driver gene mutations of GI tumors in p53 and Kras and establishment of a MHC-humanized mouse tumor model
Studentische Hilfskraft
Company Name
Universität Ulm ·Part-time
Dates Employed Aug 2006 – Sep 2009
Employment Duration ·3 yrs 2 mos
Location Ulm und Umgebung, Deutschland
Unraveling the control of octamer-dependent transcription by NFAT/NF-κB signaling in B & T cells
Education
Ruprecht-Karls-Universität Heidelberg
Ruprecht-Karls-Universität Heidelberg
Degree Name Doktor (Dr. rer. nat),
Field Of Study Biology, Tumor Immunology
Dates attended or expected graduation 2009 – 2014
Universität Ulm
Universität Ulm
Degree Name Master of Science - MS,
Field Of Study Biochemistry
Dates attended or expected graduation 2007 – 2009
Activities and Societies: Uni-Ballett Ulm
Universität Ulm
Universität Ulm
Degree Name Bachelor of Science - BS,
Field Of Study Biochemistry
Dates attended or expected graduation 2004 – 2007
Activities and Societies: Uni-Ballett Ulm
Accomplishments
Jasmin has 10 publications 10
Publications
Wnt/β-catenin activation epigenetically reprograms Regulatory T cells in IBD and progression to dysplasia •BNT162b2induces SARS-CoV-2-neutralising antibodies and T cells in humans •Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine •TCF-1 and HEB cooperate to establish the epigenetic and transcription profiles of CD4+CD8+ thymocytes. •Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses •β-catenin signaling mediates pathogenic pro-inflammatory conversion of Foxp3+ Treg cells early during colon cancer development •NF-κB-dependent signals control BOB.1/OBF.1 and Oct2 transcriptional activity in B cells •A vaccine targeting mutant IDH1 induces antitumour immunity •T cell responses against mutations in oncoproteins/tumor suppressor proteins and their induction by vaccination with long peptides •Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB
Jasmin has 5 courses 5
Courses
Basics in Economy (Grundlagen der Betriebswirtschaftslehre) •Development, permission, and controlling of drugs •Effective Writing for Life Science Research •FELASA B •Patentrecht
Jasmin has 3 languages 3
Languages
Deutsch •Englisch •Französisch
Jasmin has 2 honors 2
Honors & Awards
AAI (The American Association of Immunologists) Careers in Immunology Fellowship •CIMT 2011 Poster Award
Anyone got a linkedin account and can check her connections?
https://www.stiftung-charite.de/en/conferences/charite-entrepreneurship-summit/speakers
Speakers 2021
GAYLENE ANDERSON
Director, Global Transactions and Contracts Management, Boehringer Ingelheim Pharmaceuticals, Inc., Connecticut USA
As Boehringer Ingelheim’s Director, Global Transactions and Contracts Management, Gaylene is responsible for negotiating license/collaboration deals, research agreements, and managing strategic alliance programs. Prior to joining BI, Gaylene served as the Director, Cleveland Clinic/ University of Notre Dame Global Alliance Commercialization Program – managing all life science IP, negotiating license deals and research opportunities, and spinning out startup companies.
Throughout her career, Gaylene has had a strong focus on economic development and entrepreneurship activities. As a result, she has created over a dozen startup companies, developed relationships with investor groups around the U.S., and helped grow research collaboration opportunities for university programs. Prior to the Cleveland Clinic, she worked for the University of Idaho and the University of Hawaii, as a Senior Licensing Associate.
Gaylene has won several leadership awards for her work with faculty and students, particularly with respect to her entrepreneurial accomplishments (including her own company, Waterproof Kids®).
CHRISTOPHER BAUM
Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin, Germany
Professor Christopher Baum was born in 1962 in Marburg. He studied philosophy for two semesters in Mainz, and medicine in Essen, Freiburg and Hamburg. He obtained his doctorate in 1991, and qualified as a professor in the field of molecular medicine in 1999 at the University of Hamburg. In 2000, he joined the Hannover Medical School (MHH) as a professor for stem cell biology, and was also an associate professor of pediatrics at the Cincinnati Children’s Hospital in the United States from 2002. In Hanover, he led the Institute of Experimental Hematology from 2006 and served as both the Ombudsperson for Good Scientific Practice and the Dean of Research. He was elected President of the MHH in 2013. At the beginning of 2019, Baum moved to the University of Lübeck as its first full-time Vice President for Medicine and a member of the Board of Directors of UKSH – Germany’s second largest university hospital after Charité. Since October 2020 Christopher Baum has been Chief Executive Officer of th Berlin Institute of Health (BIH). With the integration of the BIH into the Charité – Universitätsmedizin Berlin, Baum has become Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin.
LINA BEHRENS
Managing Director at Flying Health GmbH, Berlin, Germany
Lina Behrens is a Managing Director at Flying Health, the leading ecosystem for Next Generation Healthcare. She is also Vice President of the German Startup Association and a Member of the Advisory Board „Junge Digitale Wirtschaft“ (Young Digital Economy) of the German Federal Ministry of Economics and Energy. Previously, Lina worked at the Boston Consulting Group (BCG) and at Polymath Ventures, one of the largest company builders in Latin America. Lina holds an MPA from the London School of Economics and a BA in Economics and in International Affairs from the University of St. Gallen.
JOHN S. BROWNSTEIN
Chief Innovation Officer at Boston Children’ Hospital, Boston, Massachusetts, USA
Professor of Biomedical Informatics at Harvard Medical School and is the Chief Innovation Officer of Boston Children’s Hospital. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children’s. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House. He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation and an ABC Medical News Contributor. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.
ARTHUR CAPLAN
Drs. William F and Virginia Connolly Mitty Chair Director, Division of Medical Ethics, NYU Grossman School of Medicine, NY USA
Currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.
Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.
Dr. Caplan is the author or editor of thirty-five books and over 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz) and, Getting to Good: Research Integrity in Biomedicine Springer, 2018 with Barbara Redman).
He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the co-founder and a member of the ge2p2 global foundation.
Caplan has served since 2015 as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.
Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and CNN. He appears frequently as a guest and commentator on various other national and international media outlets.
Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.
During the Covid-19 pandemic, he co-directs an advisory group on sports and recreation for the US Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines, helped set policy for WIRB/WCG for research studies He was an advisor to Moderna. And serves on the NCAA Sports and Covid committee.
He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016 the National Organization for Rare Disorders (NORD) honored him with their Rare Impact Award and hFood and Drug Law Institute’s Distinguished Service Leadership Award. In 2019 he was honored by the Food and Drug Administration’s, Reagan/Udall Foundation with its Innovation Award.
He holds seven honorary degrees from colleges and medical schools.
HORST DOMDEY
Managing Director at BioM Biotech Cluster Development GmbH, Planegg, Germany
In his scientific career, Horst Domdey worked at various German, Swiss and US institutes such as the Max Planck Institute of Biochemistry, the Swiss Institute of Cancer Research, the University of California at San Diego, the California Institute of Technology and the Munich Gene Center, where he was appointed as Professor of Biochemistry in 1994. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he is the Managing Director of BioM, the development and management organization of the Munich Biotech Cluster, since 2006 he also directs the Bavarian Biotechnology Network. Among others he is a member of the boards of the Peter and Traudl Engelhorn Foundation and the Foundation for Stem Cell Research and Applied Regenerative Medicine.
GEORG N. DUDA
Founding director of Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies (BCRT) Charité - Universitätsmedizin Berlin, Germany
Georg is the founding director of the Julius Wolff Institute at the Charité, Humboldt University and Free University of Berlin. The Julius Wolff Institute brings together researchers from engineering, mathematics, biology, biochemistry and clinical scientists in order to develop new therapeutic strategies for regeneration of injured or degenerated joint, bones and muscles. Conceptually, Georg’s research aims at understanding endogenous cascades of tissue formation, cytokine signaling and cellular self-organization especially in bone. This understanding is transferred to enable regeneration in clinically challenging healing scenarios of tissues normally capable of regeneration (bone) and those with intrinsic impaired regenerative capacity. Mechanical straining and adaptation due to mechanical cues plays a central role in all these tissues. The aim of Georg’s work is to understand the mechano-biological cues of regeneration and adaptation and how they can be employed to enable healing even in tissues with impaired regenerative capacity such as muscle, cartilage or tendon. All approaches are motivated by clinical challenges, employ basic research principles and aim at being translated into daily clinical routine. Examples of translation include innovative concepts for joint replacement procedures, angle stable fixation of implants or cell therapies for muscle regeneration.
Given his broad interest, core to all his activities is the close collaboration with clinical partners, specifically the scientific education of clinical scientists as core members of his team of research.
Georg Duda is Professor of Biomechanics and Musculoskeletal Regeneration at the Charité – Humboldt University of Berlin and Free University of Berlin and an Associated Faculty Member at the Wyss Institute for Biologically Inspired Engineering at Harvard University. He received his Master’s degree in precision engineering from the Technical University of Berlin, Germany, in 1991 and his Ph.D. degree in Mechanical Engineering from the Technical University of Hamburg-Harburg in 1996. He has been recipient of over a dozen awards for inventions, start-up engagements and PhD student mentoring.
DAME ANNA DOMINICZAK
Regius Professor of Medicine University of Glasgow, Scotland
Professor Dame Anna Dominiczak is Regius Professor of Medicine at the University of Glasgow; Honorary Consultant Physician and Endocrinologist at NHS Greater Glasgow and Clyde; and Health Innovation Champion for the Medical Research Council. In 2016, she was awarded a DBE for services to cardiovascular and medical science.
Professor Dominiczak is currently seconded to the Department of Health and Social Care in the UK Government as Director of Laboratories, NHS Test & Trace. In March 2020, she successfully led the establishment of the Lighthouse Laboratory in Glasgow (LLiG), leading to her current role where she continues to expand the Lighthouse laboratory network. She is accountable for the UK labs testing capability across a coordinated network of 13 labs. As the network continues to evolve, and very high throughput labs are brought online, Professor Dominiczak’s focus remains on delivering a triple helix partnership between academia, the NHS and industry to transform the long-term testing capability of the UK for COVID and beyond.
Recognised as a world-leading cardiovascular scientist and clinical academic, her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 500 publications), but also excels in large scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last eight years).
MARC FILERMAN
Managing Partner at German Accelerator Life Sciences, Cambridge, Massachusetts, USA
Marc Filerman is a healthtech entrepreneur and intrapreneur with expertise in market development, commercialization, and innovation acceleration. He has broad experience leading marketing, sales, and business development for large companies and startups. Marc co-founded a molecular imaging startup, was Chief Commercial Officer at an NIH-funded hometech venture, and was an Accelerator Executive with the CIMIT accelerator at Massachusetts General Hospital. Prior to his entrepreneurial endeavors Marc held corporate leadership positions in multiple large healthtech companies, including VP of Global Marketing at iCAD, Group Director of Marketing at Smith & Nephew, and Director of Global Marketing and Strategy at Hill-Rom. Marc holds BS and MS degrees from MIT in Mechanical Engineering, did his graduate work at the MIT AI Lab, and started his career as an engineer designing ultrasound imaging equipment for echocardiography.
MEREDITH FISHER
Partner at Mass General Brigham Ventures, Cambridge, Massachusetts, USA
Dr. Meredith Fisher is a Partner with the Innovation Fund focusing on early stage investments and company creation. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development at PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Meredith serves as a board member on Nocion, ClarisBio, ZielBio and Mediar Therapeutics where she is co-founding CEO. She is an Observer on Amolyt Pharma and Scorpion Therapeutics. Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University.
OLIVER HAYDEN
Heinz-Nixdorf-Chair of Biomedical Electronics, Director TranslaTUM at TU München, Germany
Employment
03/2019
Director of the Center for Translational Cancer Research (TranslaTUM), Campus University Hospital Klinikum rechts der Isar, TUM, Germany
06/2017
Heinz-Nixdorf-Chair of Biomedical Electronics, Department of Electrical and Computer Engineering, TU Munich, Germany
11/2016 - 05/2017
Head of In-Vitro Diagnostics & Bioscience Germany, Siemens Healthcare GmbH, Technology Center, Erlangen, Germany
05/2015 - 10/2016
Senior Key Expert Scientist at Siemens Healthcare GmbH, Technology Center, Erlangen, Germany
05/2007 - 04/2015
Program Manager at Siemens AG, Corp. Technology, Erlangen, Germany
08/2005 - 04/2007
Visiting Scientist at IBM Research GmbH, Zürich Research Laboratory, Rüschlikon, Switzerland
01/2000 - 07/2005
Assistant Professor at the Institute of Analytical Chemistry, University of Vienna, Austria
Awards
2017 - European Inventor Award (category industry for hematology analysis of Plasmodium infections, Patent EP 2 635 695 B1, 2011)
2016 - Innovation Award of AMA (Association for Sensors & Measurement)
2013 - Siemens NTF Award for Medical Imaging IP portfolio 2006 EUREKA Lillehammer Award (E! 2497 Euroenviron BIOMAC) 2002 Young Investigator Award of the Austrian Chemical Society
2000/2001 - Award winner of “Best of Biotech” for start-up competition “Polymimetics”
Research Expertise & Interests
-
Current research @ TUM: in vitro & in vivo diagnostics
-
Industrial research: 12yrs in the semiconductor and healthcare industry on post-CMOS, medical imaging, in vitro diagnostics, and bioscience topics
-
Academic training: 5yrs on piezoacoustic sensing and semiconducting nanowire sensing
ANH HOANG
Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA
Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.
Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.
Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.
ANH HOANG
Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA
Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.
Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.
Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.
LUCIO IANNONE
Senior Director Venture Investments Leaps by Bayer, Cambridge, MA, USA
Lucio Iannone is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Lucio is responsible for developing investment cases and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is serving as board member for Pyxis Oncology, Khloris Biosciences, Vesigen Therapeutics , Immunitas Therapeutics, eGenesis, Azitra, Kojin Therapeutics and Axxam. Before joining Leaps by Bayer, he had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio obtained his Ph.D. in Medicine at the Imperial College of London and Master in Molecular Biology from Cambridge University.
REGINA HODITS
Managing Partner at Wellington Partners Life Sciences (WPLS), Munich, Germany
Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences.
Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star (NASDAQ,: FSTX) and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey.
Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK.
KATALIN KARIKÓ
Senior Vice President RNA Protein Replacement Therapies at BioNTech, Mainz, Germany
Katalin Karikó is Senior Vice President at BioNTech RNA Pharmaceuticals from 2013. She is also Adjunct Associate Professor at the Perelman School of Medicine, University of Pennsylvania, where she worked for 24 years. She received her PhD in biochemistry from University of Szeged, Hungary, in 1982. For four decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered that nucleoside modifications suppress immunogenicity of RNA. This groundbreaking work unlocked the opportunity for the therapeutic use of mRNA. Her patents, co-invented on nucleoside-modified uridines of mRNA, was the foundation for the FDA-approved anti-SARS-CoV-2 mRNA vaccines developed by BioNTech/Pfizer and Moderna/NIAID that are crucial to ending the global pandemic.
SEKAR KATHIRESAN
CEO at Verve Therapeutics, Cambridge, USA
Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics and serves on the company’s board of directors. He is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. His research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. Among his scientific contributions, he has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention. He was honored with a Distinguished Scientist Award from the American Heart Association in 2017 and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus was the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
HEYO K. KROEMER
Chief Executive Officer at Charité – Universitätsmedizin Berlin, Germany
A pharmacologist by trade, Prof. Kroemer was born in 1960 in the Eastern Friesland area of Germany, Prof. Kroemer trained as a pharmacologist. From 2000 to 2012, he was Dean of the Medical School at the institution now known as the University of Greifswald. In 2011, he was appointed Scientific Director of Universitätsmedizin Greifswald. After joining the Board in 2007, Prof. Kroemer became President of the German Association of Medical Faculties (MFT) in 2012, a position he held until 2019. During this time, he was both Dean and Chairman of the Board of the University of Göttingen Medical Center. Prof. Kroemer was appointed Charité’s Chief Executive Officer on 1 September 2019.
MADELEINE KÜNZ
Senior Consultant – Market Access & Regulatory Strategie at Kalms Consulting, Berlin
Dr. Madeleine Künz academic background is reseach in Molecular Life Sciences, Structure Biology and Chemistry. Before joining Kalms Consulting, she worked for over 10 years in international research facilities and the pharmaceutical industry. Her research mainly concentrated on rational drug development in international interdisciplinary working groups combining approaches from structural biology, biophysics and chemistry. Her understanding of medical technologies is supported by her additional education and work experience as a paramedic for 7 years as well as advanced education in health technology assessment (HTA). Especially diagnostic but also therapeutic procedures including digital health products are part of her expertise. Furthermore, differentiation as well as compatibility assessments allow her to draw an accurate picture of innovation´s value. Her work in Kalms Consulting is centered around the assessment of innovative technologies and translation of these into options for the regulatory and market access strategy.
JASON LEITCH
National Clinical Director at Scottish Government, Scottland
Jason has worked for the Scottish Government since 2007 and in January 2015 was appointed as The National Clinical Director in the Health and Social Care Directorate. He is a Scottish Government Director and a member of the Health and Social Care Management Board. He is one of the senior team responsible for the NHS in Scotland.
He is an Honorary Professor at the University of Dundee.
Jason was the 2011 UK Clinician of the Year.
He is a Senior Fellow at the Institute for Healthcare Improvement (IHI). He was a 2005-06 Quality Improvement Fellow at IHI, in Boston, sponsored by the Health Foundation.
SARAH LEVY-SCHREIER
CTO at Sight Diagnostics
Sarah joined Sight to build and lead its technology dream-team. She is responsible for all of Sight's R&D as well as its medical-regulation activities. Top of her class at the elite Talpiot program, Sarah gained her technology leadership experience during a brilliant military career, where she commanded elite cyber security and intelligence special technology units.
Sarah holds as M.Sc. in Condensed Matter Physics from the Weizmann Instituter of Science, and a B.Sc in Physics & Mathematics (magna cum laude) from the Hebrew University of Jerusalem.
NEEMA MAYHUGH
Managing partner and founder WAVE STRATEGY, Cleveland, Ohio, USA
MANAGING PARTNER
Neema Mayhugh is a healthcare innovation expert who helps large academic medical centers and biotechnology incubators bridge the gap between research and product delivery. Neema designs and executes a comprehensive strategy to take technology from bench to bedside -- engaging partners, securing capital, and delivering desired outcomes, always with an eye toward ensuring the highest quality patient care and enhancing the patient experience.
Built on a solid foundation of clinical innovation, Neema’s expertise stems from strong basic research training and early positions in healthcare management consulting and with Pfizer, Inc. Her specialization then grew rapidly when she joined the industry-leading Cleveland Clinic, where her roles and responsibilities expanded to include:
~ Start-up formation
~ Licensing
~ Intellectual property portfolio prioritization
~ Clinical trial management and execution
~ Sponsored research program negotiation
~ Management of commercialization projects
~ Strategic portfolio oversight
As Chief Operating Officer of Mobile Hyperbaric Centers, Neema expanded her expertise base again, overseeing operations for seven hospital centers and all corporate functions including insurance authorization, billing, documentation, compliance, human resources and center safety and maintenance.
Neema holds a Doctoral degree in Pharmacology & Toxicology from Dartmouth College and a Bachelors of Science in Human Physiology from Boston University.
NICHOLAS MILLS
Chair of Cardiology & Consultant Cardiologist at University of Edinburgh
Current post: British Heart Foundation (BHF) Butler Senior Clinical Research Fellow (personal fellowship, 2016-2021) and Personal Chair of Cardiology, BHF/University Centre for Cardiovascular Science, University of Edinburgh. Consultant Interventional Cardiologist, Royal Infirmary of Edinburgh.
Previous appointments:
2013 - 2015 Reader in Cardiology, University of Edinburgh
2011 - 2016 BHF Intermediate Clinical Research Fellow, University of Edinburgh
2011 - 2013 Senior Lecturer in Cardiology, University of Edinburgh
2007 - 2011 Clinical Lecturer in Cardiology, University of Edinburgh
2005 - 2011 Specialist Registrar in Cardiology, Royal Infirmary of Edinburgh
2005 - 2007 Michael Davies/British Cardiac Society Research Fellow, University of Edinburgh
2003 - 2005 British Heart Foundation Research Fellow, Edinburgh University, Edinburgh
2001 - 2003 South East of Scotland Senior House Officer Rotational Training Scheme in Medicine
2000 - 2001 Pre-registration House Officer Posts, Western General Hospital, Edinburgh
Education:
BSc (First Class Honours) Edinburgh University 1998
MB ChB Edinburgh University 2000
MRCP Royal College of Physicians 2003
PhD Edinburgh University 2009
Selected Grants:
British Heart Foundation UK Cardiovascular Regeneration Medicine centre Award Renewal (RM/17/3/33381). 2017 for 4 year (£2.5 million). (Principal Investigator, Prof Andrew Baker).
Duration of dual anti-platelet therapy in acute coronary syndrome across Scotland. The DUAL-ACS2 Trial. BHF Clinical Study Grant (CS/17/4/32960). 2017 for 5 year (£630k). (Principal Investigator, Prof David Newby).
Refining the diagnosis of type 2 myocardial infarction. BHF Clinical Research Training Fellowship (FS/16/75/32533). 2016 for 3 years (£283k) for Dr Andrew Chapman.
High-sensitive cardiac troponin and coronary heart disease. BHF Butler Senior Clinical Research Fellowship (FS/16/14/32023). 2016 for 5 years (£1.2m).
Identification and characterisation of a vessel wall endothelial progenitor cell, and its potential for vascular regeneration. BHF Intermediate Research Fellowship (FS/16/4/31831). 2016 for 4 years (£540k).
High-sensitivity cardiac troponin on presentation to rule out myocardial infarction (HiSTORIC): A randomised controlled trial. BHF Project Grant (PG/15/51/31596). 2015 for 3 years (£272k)
BHF UK Cardiovascular Regenerative Medicine Centre Award (RM/13/2/30158). 2013 for 4 years (£2.5m).
Lipid mediators as predictors of nanoparticle-induced cardiovascular disease. BHF Special Project Grant (SP/15/8/31575). 2015 for 4 years (£538k).
Development of a clinical translational model of arterial injury and repair to assess vascular stem cell therapies. BHF Project Grant. 2013 for 3 years (£299k).
High-sensitive troponin in the evaluation of patients with acute coronary syndrome (HighSTEACS): A randomised controlled trial. BHF Special Project Grant (SP/12/10/29922). 2012 for 3 years (£702k)
YAAKOV NAHMIAS
Professor and Director Center for Bioengineering at The Hebrew University of Jerualem, Israel
Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technion, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem. Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Nahmias is the co-founding director of BioDesign-Israel an entrepreneurship program that educated over 120 fellows, and launching 6 startup companies including Guide In Medical, CardioVia and Swiftduct. Nahmias is the founder and CSO of two biotechnology startups, including Tissue Dynamics that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded Future Meat Technologies focusing on the cost-effective production of cultured meat.
YORAM PALTI
Professor Emeritus Physiology and Biophysics Technion University, Israel; Founder and Chief Technology Officer Novocure, Israel
Professor Yoram Palti received his M.Sc., Ph.D. and M.D. from The Hebrew University Hadassah Medical School, Jerusalem. He was appointed an Associate Professor of Physiology at the University of Maryland School of Medicine in 1969 and an Assoc Prof. of Physiology and Biophysics at the Technion Medical School in 1971 and Full Prof. in 1976. Currently he is Prof. Emeritus at the Technion.
Palti served as the Head of the Dept. of Physiology & Biophysics (1971- 1991) and as the Head of the Rappaport Family Institute for Research in the Medical Sciences, the research arm of the Technion, from its establishment in 1982 till 1993.
Professor Palti has founded several startup companies, for example: Carmel Biosensors, Echosense, O2Cure, BG Guard and the highly successful Novocure that was established in 2000 and currently has a Cap value of over $20 Billion (NVCR). At NovoCure Palti served as Director through 2018 and serves as the company’s Chief Technology Officer to date.
NINA RAWAL
Founder of Emerging Health Ventures, Stockholm, Sweden
Dr. Nina Rawal is the founder of Emerging Health Ventures. Previously, she headed the life science investment team at Industrifonden, a 600 million EUR venture capital fund. Previous experience also includes of Vice President, Strategy and Ventures at Gambro AB, and management consulting at Boston Consulting Group in Stockholm and New York. She serves on the boards of MedCap AB (publ) and Stockholms Sjukhem, a non-profit hospital and health care organization. She holds a PhD in Molecular Neurobiology, and a MSc in Biomedicine, both from the Karolinska Institute, including research work done at Columbia University in New York and at Hôpital la Salpêtrière in Paris.
Recognition for her work includes the selection as a Young Global Leader by the World Economic Forum and a '40 under 40 - European Young Leader' by Friends of Europe/Europanova.
GUR ROSHWALB
Partner at aMoon, Ra'anana, Israel
Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies. Beginning his career as a practicing physician, Gur understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice. Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.
NIELS SHARMAN
Investment Analyst at HTGF, High-Tech Gründerfonds, Bonn, Germany
Niels Sharman is an Investement Analyst within the Life Sciences team of HTGF. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and contributed to a biotech start-up.
MILDRED Z. SOLOMON
President at The Hastings Center, Garrison, New York USA
Mildred Z. Solomon, EdD is the President of The Hastings Center, the nation’s founding bioethics research institute, focused on examining the social and ethical implications of health and health care, science, and emerging biomedical technologies. She is also Professor (part-time) of Global Health and Social Medicine at Harvard Medical School, where she runs a Fellowship in Bioethics and has trained over 200 scientists, physicians and other kinds of professionals from across the United States and around the world. Dr. Solomon’s own research covers a broad spectrum of topics -- including, for example, the ethics of end-of-life care, organ transplantation, medical professionalism, and responsible conduct of research. She recently completed a two-year term on the World Economic Forum’s Global Futures Council on Technology, Values and Policy. She has served on committees of the National Academies of Sciences, Engineering and Medicine, on the US Secretary of Health and Human Services’ Advisory Committee on Organ Transplantation, and is currently a member of the Global Health Advisory Committee of the Open Society Foundations’ Public Health and Human Rights Programs. Dr. Solomon has over 70 academic publications in peer-reviewed journals and is also frequently cited in the mainstream media, including the Wall Street Journal, National Public Radio, New York Review of Books, The Daily Beast, Forbes, Science News, The Scientist and other outlets. A frequent public speaker, she has presented at Aspen Health, the New York Academy of Sciences, academic medical centers, and numerous public venues. Before leading The Hastings Center, she was Senior Director for Implementation Science at the Association of American Medical Colleges and before that, Vice President of Education Development Center, an independent research institute in Boston, MA. Dr. Solomon holds a B.A from Smith College and a doctorate in educational research methods from Harvard University.
ANETTE STRÖH
Project Manager Digital Health and Scouting at BIH Digital Labs, Berlin, Germany
2007 Diploma Product Design, Bauhaus University Weimar
2010 MA Medical Design, Muthesius School of Arts, Kiel
2011-2015 Brand Strategist, f+d design studios, Hamburg
2015 Consultant, diffferent strategy consultancy, Berlin
2015-2017, Design Lead Participatory Health Unit , IXDS, Berlin
2017-2020, Service Design Lead, designit Germany, Berlin
since Dec 2020, Project Manager Digital Health and Scouting, Berlin Institute of Health, Berlin
ALEX WALDRON
CEO at Wellinks, New Haven, Connecticut, USA
Alex Waldron is Chief Executive Officer at Wellinks, a COPD-focused digital health company fueled by a mission to empower people in their pursuit to breathe freely. Wellinks’ lead asset is a digitally enabled and outcomes-driven holistic virtual care management solution for COPD, with a focus on reinventing respiratory care. The company’s expertise in COPD innovation began with the development and FDA 510(k) clearance of Flyp Nebulizer, the first truly pocket-portable nebulizer, allowing patients simple, convenient, and connected access to breathing treatments. Wellinks connects individuals and their caregivers through a suite of medical devices and intuitive software, enabling virtual COPD care management based on information that is real-time, accurate, and actionable.
Executive global bio/pharmaceutical business leader with 25+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.
JACKIE WARING
Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Scotland
Jackie Waring MA (Hons), DMS, DipM, MSc Founder & CEO, Investing Women Angels & AccelerateHER
Jackie is a pioneer of women angels ‘changing the face of angel investing’; bringing more women angels into Scotland’s dynamic angel investment community. An active and experienced angel investor herself; she established and leads Scotland’s all-female angel group Investing Women Angels whose members have invested over 80% of their funds in highly innovative female founded/co-founded companies.
Jackie is an entrepreneur with a passion for helping other entrepreneurs. It was this passion which inspired her to establish AccelerateHER; creating a channel and direct help for female founders going for scale. Publicly recognised by Scotland’s First Minister; she is a major player in shaping the ScotCanDo eco-system. The AccelerateHER Awards, workshops, mentoring and other support are achieving tangible impact; boosting the volume and investment in Scotland’s female-led companies. She has also nurtured strong international partnerships leading to regular AccelerateHER missions to Silicon Valley, Dubai, Berlin; and now Boston and New York in partnership with Founders Forum:
Jackie has previously run three companies, including 10 years CEO of a business/economic development organisation in Scotland. She has also been an external policy advisor to UK government; leading on the access to finance agenda for women entrepreneurs.
RICHARD YOUNG
Professor at Whitehead Institute/MIT, Cambridge, Massachusetts, USA
Richard Young is a Professor at the Whitehead Institute and MIT. Dr. Young studies gene regulation in health and disease and has mentored more than 100 graduate and postdoctoral students, many of whom now lead academic and commercial research programs and enterprises. Young has served as an advisor to the World Health Organization, the National Institutes of Health and numerous scientific societies and journals. His honors include Membership in the National Academy of Sciences and the National Academy of Medicine, and Scientific American has recognized him as one of the top 50 leaders in science, technology and business. He has founded and advised companies in the biotechnology and pharmaceutical industry, and currently serves on the boards of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. Young is also an aviator and holds a commercial pilot license.
https://www.stiftung-charite.de/en/conferences/charite-entrepreneurship-summit/advisory-board
Advisory Board Members
IDA BEERHALTER
Spokeswoman, Summit Advisory Board & Co-Head, IOME
Ida Beerhalter is Co-Head of IOME, a private investment partnership of women principals from the Gulf region with its head office in Riyadh, KSA.
Additionally, Mrs Beerhalter also serves as Member of the Board, Trustee, Advisor and Expert to various for-profit and not-for-profit organizations around the globe (amongst others Astia, Auma Obama Foundation Sauti Kuu, Omnia Strategy, First Light Trust, Women Political Leaders (WPL) Global Forum, slavefreetrade.org, Professors Without Borders, Yunus Social Business, TBLI Group The Netherlands, Charité Foundation Summit Germany). She is specialized in a wide range of issues including investing & wealth management , entrepreneurship, social business & impact investment, gender inclusiveness, women empowerment, education, emerging markets and family governance and succession planning.
CHARLIE CAMERON
Senior Vice President, Business Development, Cooley
Charlie Cameron has over 25 years of business development, investing and management consulting experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies, judges numerous business plan competitions and is a frequent speaker on innovation and entrepreneurship. He founded the Hub Angel Investment Group, which is on its fifth fund. He works with a plethora of entrepreneurs, innovators and investors in Europe, with special focus on DACH countries. Charlie is also Senior VP of Strategy at Cooley LLP, a global law firm with deep experience working with life science and tech companies and venture funds. He is on the board of the German American Business Council, Boston, the advisory board of the German Accelerator Life Science, and several other boards and advisory groups. During the past decade, Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Massachusetts.
JOHN HALLINAN
Chief Development Officer, Danforth Advisors, Waltham, MA
JOHN HALLINAN John Hallinan joined Danforth Advisors in 2020 as the Chief Development Officer. John’s experience in the life sciences reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions. Prior to Danforth Advisors, John was the Chief Business Officer at MassBio and Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University. Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading biopharma applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding. John serves on the Advisory Board of the Charité BIH Entrepreneurship Summit and the Advisory Board of the Massachusetts Technology Transfer Center (MTTC), and proud to serve as a mentor in MassCONNECT, the premier mentoring program for early-stage companies and aspiring entrepreneurs.
JOANN HALPERN
Director, Hasso-Plattner-Institut, New York
Dr. Joann Halpern is the New York Director of the Hasso-Plattner-Institut für Digital Engineering (HPI) and an Adjunct Professor of International Education at New York University. Before joining HPI, Halpern lived in Cologne, Germany and helped to prepare a new, global university for accreditation. She moved to Cologne from New York City where she was Founding Director of the German Center for Research and Innovation (GCRI).
Prior to joining the GCRI, Dr. Halpern was Director of Academic Affairs and Senior Studies and Assistant Professor of International Education at Global College of Long Island University. She also co-founded Knowledge Transfer Beyond Boundaries, an NGO with projects in Cameroon, Nigeria, and Yemen. From 1996 to 2001, Halpern was Director of International Programs at Harz University of Applied Sciences in Wernigerode, Germany. She received her B.A. from Dartmouth College, her M.A. from Harvard University, and her Ph.D. from New York University. Dr. Halpern is a recipient of the Harvard Award for Distinction in Teaching as well as scholarships and fellowships from the Fulbright Association, German Academic Exchange Service, Robert Bosch Foundation, and the National Endowment for the Humanities. She serves on the advisory boards of the Charité Entrepreneurship Summit, German Accelerator, Technical University of Dortmund, University Alliance Ruhr, and Virtual Enterprises International.
ANULA JAYASURIYA
Founder, eXXclaim Capital, EILSF
Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula’s expertise consists of a unique combination of business, basic science and medical knowledge.
Recognizing the growing yet under-invested opportunity in Women’s Health, in 2013 Anula launched eXXclaim Capital, focused on catalyzing innovation, entrepreneurship and investment in this field and has already made several investments. In 2006 Anula co-founded the “Evolvence India Life Science Fund” (EILSF), to make investments in pharmaceutical, biotechnology, medical device and contract services companies based in India. EILSF has garnered three successful exits to date and India Life Science 11 has had its first close.
She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, in England. Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, Hyderabad and nVision, San Francisco. She was previously a board member of Health Care Global which was exited to Temasek, Lipomics which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.
MARKUS MÜSCHENICH
Co-Founder & Managing Partner, Flying Health Incubator
Markus Müschenich is a board certified pediatrician and has a degree in Public Health. He is the founder of ConceptHealth, a think tank with longterm expertise in strategic business development based on health care's future foresight analysis. After more than ten years membership of executive boards in private and nonprofit hospital companies, Dr. Müschenich co-founded FLYING HEALTH a German company builder and business developer for health startups. FLYING HEALTH partners with founders, connects geeks and healthcare professionals and supports R&D for innovative products and services gaining market access. Dr. Müschenich is member of the board of directors of the German Association for Internet Medicine.
ANNIKA PIERSON
Annika Pierson, Co-Founder & Chief Operating Officer, Advise Connect Inspire
Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. As Chief Operating Officer of ACI, she facilitates the successful US market entry of emerging companies from Europe and connects US-based startups with European investors and industry groups. Prior to joining the German Accelerator Life Sciences (GALS) and founding ACI in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Charité Foundation in Berlin, including the highly successful international healthcare industry conference, Charité Entrepreneurship Summit.
JOACHIM RAUTTER
Co-Founder, Peppermint VenturePartners
Joachim Rautter is a co-founder of Peppermint VenturePartners and Managing Partner of Peppermint Charité Biomedical Fund.
Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CryoTherapeutics GmbH and Labfolder GmbH.
Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies.
Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.
there are also multiple archived ones
-
Foundation Charite, which is separated in speakers 2021 and advisory board, board of trustees, and everything else
-
then there is this Jasmin QUANDT Scientist at BioNTech
Bundling everything together is not good imo
Why though? Simply split them up accordingly.
We don't know for sure if Jasmin Quandt is part of that family, but it's highly likely.
Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)
https://www.linkedin.com/in/rob-quandt-21229b34/
https://archive.is/zTh6s
Associate Creative Director at WILDTYPE
Brooklyn, New York, United States
About
Therapeutic categories: Aesthetics, Allergy, Alzheimer’s, Assisted reproduction, Asthma, Cardiovascular, COPD, Dermatology, Diabtetes, Gastrointestinal, Hyperuricemia/gout, Infection, Oncology, Pain management, Rheumatoid arthritis, Women’s health/gyn, Vaccines
Experience
WILDTYPE, a TBWA\WorldHealth Company
Associate Creative Director
Company Name
WILDTYPE, a TBWA\WorldHealth Company ·Full-time
Dates Employed 2018 – Present
Employment Duration ·3 yrs
Location Greater New York City Area
Keytruda (oncology) - Merck
Welireg (VHL disease) - Merck
Ontruzant (oncology) - Merck Biosimilars
Aybintio (oncology) - Merck Biosimilars
Freelance Various
Freelance Associate Creative Director
Company Name
Freelance Various
Dates Employed 2010 – Present
Employment Duration ·11 yrs
Location Greater New York City Area
MRM/McCann - Shingrix
CDM NY - Xifaxan
Biolumina - Zometa
Cementbloc - Cimzia
DraftFCB - Amyvid, Solanezumab
Harison & Starr - Genetech Bio-oncology
StrikeforceNYC - Paragard
Havas Life - Meade Johnson, Milprosa, Restylane, Dysport, Walgreens, Biogen
Havas Lynx - Sarilumab
Havas Life Metro - Admelog, Soliqua
Digitas Health - Linzess, Eliquis
Ogilvy Commonhealth - Striverdi
Grey Group
Associate Creative Director
Company Name
Grey Group ·Freelance
Dates Employed 2014 – 2018
Employment Duration ·4 yrs
Location Greater New York City Area
Basaglar (T2 diabetes) - Eli Lilly
Olumiant (RA) - Eli Lilly
Taltz (psoriatic arthritis) - Eli Lilly
Xalkori (oncology) - Pfizer
BGB Group
Associate Creative Director
Company Name
BGB Group ·Freelance
Dates Employed 2012 – 2014
Employment Duration ·2 yrs
Location New York, United States
Movantik (opioid-induced constipation) - AstraZeneca
Opdivo (oncology) - AstraZeneca
Ogilvy & Mather
Associate Creative Director
Company Name
Ogilvy & Mather ·Full-time
Dates Employed 2007 – 2010
Employment Duration ·3 yrs
Location Greater New York City Area
Flibanserin (women's health) - Boehringer
Tygacil (antibiotic) - Wyeth
Relistor (mu-opioid inhibitor) - Wyeth
Qlaira (contraception) - Bayer
Natrelle (aesthetics) - Allergan
Juvederm (aesthetics) - Allergan
Latisse (aesthetics) - Allergan
SAATCHI & SAATCHI HEALTHCARE COMMUNICATIONS, INC.
Copy Supervisor
Company Name
SAATCHI & SAATCHI HEALTHCARE COMMUNICATIONS, INC. ·Full-time
Dates Employed 2005 – 2007
Employment Duration ·2 yrs
Location Greater New York City Area
Enbrel (RA) - Amgen
Ambien (insomnia) - Sanofi
Ambien CR (insomnia) - Sanofi
Elitek (hyperuricemia) - Sanofi
Education
Fordham University - Graduate School of Business Administration
Fordham University - Graduate School of Business Administration
Degree Name Master of Business Administration - MBA,
Field Of Study Finance
Dates attended or expected graduation 1995 – 1998
Providence College
Providence College
Degree Name BS,
Field Of Study Marketing
Dates attended or expected graduation 1989 – 1993
New York University
New York University
Field Of Study Digital Media
Dates attended or expected graduation 1999 – 2000
Universität Salzburg
Universität Salzburg
Dates attended or expected graduation 1994 – 1994
Skills & endorsements
Creative Strategy
See 27 endorsements for Creative Strategy ·27
person
Endorsed by Davar Azarbeygui and 4 others who are highly skilled at this
company
Endorsed by 3 of Rob’s colleagues at Grey Group
Interactive Advertising
See 21 endorsements for Interactive Advertising ·21
person
Endorsed by Andrew Bartel and 1 other who is highly skilled at this
company
Endorsed by 2 of Rob’s colleagues at Grey Group
Advertising
See 17 endorsements for Advertising ·17
person
Endorsed by Davar Azarbeygui and 5 others who are highly skilled at this
company
Endorsed by 2 of Rob’s colleagues at Grey Group
Oh and that Drosten female that got 250.000 EUR from that Quandt-Foundation, that's ALSO separate and it's actually very very important.
Please add Jasmin Quandt - "Scientst at BioNTech, involved in BNT162b2 gene therapy development"
Also add to Sandra Ciesek - "in a team with PCR-test-Drosten, received 250.000 EUR in March from Charite Foundation / Quandt"
Foundation Charite - "2 Quandt family members on the board of trustees"
Charite Advisory Board Members -Charité Foundation Advisory Board Members
aslo Rob QUANDT has to be added too, I just posted that one
"(Ex-Associate Creative Director Pfizer/AstraZeneca)"
Updated:
>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts
>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members
>>79372 How common is the name Quandt in Germany? Pretty rare
>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers
>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2
>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)
>>79343, >>79343, >>79352 Foundation Charite site
>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.
>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, received a grant of 250.000 EUR from Charite Foundation/Johanna-Quandt-Foundation in March 2020
Please verify
>involved w/ PCR-Test-Drosten
add:
"found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus"
MOST IMPORTANT
Updated:
>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts
>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members
>>79372 How common is the name Quandt in Germany? Pretty rare
>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers
>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2
>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)
>>79343, >>79343, >>79352 Foundation Charite site
>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.
>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus, received a grant of 250.000 EUR from Charite Foundation/Quandts